Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Liquisolid technique as a tool for enhancement

430 views

Published on

Project

Published in: Education
  • Fact: Penis Enlargement CAN Work. Here's How. ★★★ https://bit.ly/30G1ZO1
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Liquisolid technique as a tool for enhancement

  1. 1. B y M r . M e g h r a j S u r y a w a n s h i , M r s . S h e f a l i D h a v a d e G u i d e D r . S . B . B u m r e l a S i n h g a d I n s t i t u t e o f P h a r m a c e u t i c a l S c i e n c e s K u s g a o n ( B k ) l o n a v a l a , P u n e - 4 1 0 4 0 1 “LIQUISOLID TECHNIQUE AS A TOOL FOR ENHANCEMENT OF DISSOLUTION PROFILE OF POORLY SOLUBLE DRUG: LORNOXICAM” 1
  2. 2. INTRODUCTION  Solubility is defined as the concentration of the solute in a saturated solution at specified condition.  The drug solubility in solution is static property and drug dissolution rate is dynamic property.  Solubility is one of the important parameters to achieve desired concentration of drug in systemic circulation for achieving pharmacological response.  Currently only 8% of new drug candidates have both high solubility and permeability. 2
  3. 3. NEED AND OBJECTIVES  NEED OF PRESENT INVESTIGATION:  Liquisolid compact are used to enhance the solubility and dissolution rate of poorly water soluble drugs.  Lornoxicam is non-steroidal anti-inflammatory drug (NSAIDS) that belongs to oxicam class and is freely soluble in NaOH, whereas it is practically insoluble in water.  It is belongs to (CLASS II) drugs which are poorly soluble, highly permeable. 3
  4. 4. OBJECTIVES  To enhance the solubility of poorly water soluble drug like Lornoxicam.  To formulate and evaluate liquisolid compact of Lornoxicam.  To compare dissolution profile of liquisolid compact of Lornoxicam with conventional tablets of Lornoxicam.  To study the effect of different concentration of nonvolatile vehicle used on drug release.  To study the effect of different ratios of carrier and coating material used on drug release. 4
  5. 5. Method of liqui-solid compact Lornoxicam + Non-volatile vehicle (PG, PEG, Cremophor EL) Carir (Avicel PH 102) + Coating material (Cab-O-Sil M5) Disintegrant (polyplasdone XL-10) Powder Mixture Compact/ Tablet Addition Trituration Mixing for 10min Direct Compression 5
  6. 6. Optimization  Effect of different drug concentration in liquid vehicle on drug release from lornoxicam liquisolid compacts by direct compression method  Effect of different ratios of carriers on drug release of lornoxicam liquisolid compact. 6
  7. 7. Characterization  Pre-compression study  FTIR  DSC  Flow properties  Compact/tablet evaluation  Weight variation  Hardness  Assay  Content uniformity  Friability  In-vitro disintegration  In-vitro dissolution 7
  8. 8. Saturation solubility data of lornoxicam Solvents Solubility (mg/ml) Cremophor-EL 0.842 mg/ml Propylene glycol 0.2842 mg/ml Polyethylene glycol- 400 0.75 mg/ml Water 0.0003 mg/ml 8
  9. 9. Determination of angle of slide for various excipients 9
  10. 10. Flowable liquid retention potential for carrier and coating material (Φ- value) Excipient Φ Value PEG400 Propylene glycol CremophorEL Avicel102 0.005 0.16 0.27 Cab-o-sil M-5 3.26 3.31 0.9 10
  11. 11. Liquid load factor different ratios of carrier and coating material (Φ- value) Sr. No Liquid vehicle R value Lf value 1 PG 10 0.491 20 0.325 2 PEG400 10 0.331 20 0.168 3 Cremophor EL 10 0.360 20 0.315 11
  12. 12. Lornoxicam Liquisolid tablet evaluation Liquisolid system tablet evaluation LS Tab. weight (mg) Diameter (mm) Thickness (mm) Width (mm) Length (mm) Hardness (N) D.T (min) LS-1 136 ±5 3.8 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 1.5 ±0.3 LS-2 177±5 8.1 ±0.2 3.2 ±0.2 40-50 1.5 ±0.3 LS-3 90±5 2.7 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 2.1 ±0.3 LS-4 188±5 8.1 ±0.2 3.3 ±0.2 40-50 1.39 ±0.3 LS-5 68±5 5.3 ±0.2 2.4 ±0.2 40-50 2.8 ±0.3 LS-6 88±5 2.6 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 1.4 ±0.3 LS-7 181±5 8.1 ±0.2 3.3 ±0.2 40-50 1.53 ±0.3 LS-8 304±5 9.1 ±0.2 4.7 ±0.2 40-50 1.52 ±0.3 LS-9 121±5 3.6 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 1.5 ±0.3 LS-10 202±5 8.1 ±0.2 4.1 ±0.2 40-50 2.1 ±0.3 LS-11 90±5 2.7 ±0.2 4.6 ±0.2 8.1 ±0.2 40-50 1.31 ±0.3 LS-12 152±5 8.1 ±0.2 3.1 ±0.2 40-50 1.53 ±0.3 LS-13 170±5 8.1 ±0.2 3.1 ±0.2 40-50 1.22 ±0.3 LS-14 182±5 8.1 ±0.2 3.2 ±0.2 40-50 1.56 ±0.3 LS-15 113±5 3.1 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 1.45 ±0.3 LS-16 121±5 3.4 ±0.2 4.6 ±0.2 8.1 ±0.2 40-50 2.11 ±0.3 LS-17 85±5 2.4 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 1.39 ±0.3 LS-18 90±5 2.7 ±0.2 4.5 ±0.2 8.1 ±0.2 40-50 1.49 ±0.3 DCT 100 ±5 3.1 ±0.2 4.4 ±0.2 8.1 ±0.2 40-50 1.39 ±0.3 12
  13. 13. Assay, Content uniformity and Friability data for lornoxicam liquisolid tablet Liquisolid System % Assay Content Uniformity (%) Friability (%) LS-1 89.31± 5 97.2 ± 2 0.126 LS-2 105.6 ± 4.1 98.2 ± 3.1 0.156 LS-3 96.25 ± 3.5 101.2 ± 2.1 0.135 LS-4 106.2 ± 4.6 99.2 ± 1.1 0.128 LS-5 91 ± 5.3 99 ± 1.6 0.102 LS-6 95.2 ± 2 98.3 ± 1.3 0.11 LS-7 96.8 ± 6 97.9 ±2.1 0.187 LS-8 100.6 ± 3.2 100.2 ±3.1 0.17 LS-9 108.7 ± 6.3 100.6 ± 2.1 0.131 LS-10 90.8 ± 5.2 101 ± 1.5 0.0152 LS-11 96.8 ± 6.1 98.9 ± 1.6 0.166 LS-12 100.6 ± 1.5 99.2 ± 1.3 0.162 LS-13 101.25 ± 4 99.8 ± 1.4 0.103 LS-14 98.75± 2.6 100.6 ± 2.4 0.0891 LS-15 100.62 ± 2.5 100.1 ±2.1 0.126 LS -16 94.3 ± 3.6 98.6 ± 2.6 0.156 LS-17 96.25 ±4.8 97.8 ± 2.7 0.105 LS-18 99.37 ± 3.7 100.1 ± 1.9 0.154 DCT 100 ± 6.1 99.2 ± 2.3 0.013 13
  14. 14. 14
  15. 15. Conclusion  The studies suggested that lower drug concentration in Cremophor EL gives enhanced dissolution profile.  LS-LXM-14 formulation showed complete release of drug within 10min in phosphate buffer pH 7.4 dissolution media.  Powder substrate ratio(R=20) was found to give good release profile as compare to other ratioR20>R10.  The present investigation showed that liquisolid formulation can be used to enhance the solubility of poorly soluble drug like LXM. 15
  16. 16. References  Jain P, Goel A, Sharma S. and Parmar M. Solubility enhancement techniques with special emphasis on hydrotrophy. International Journal of Pharmacy Research. 2010; 1(1):34-45.  Yellela S. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. Journal of Bioequivalence and Bioavailability. 2010; 29(2):028 – 036.  Vemula V, Lagishetty V and Lingala S. Solubility enhancement techniques. International Journal of Pharmaceutical Science Review and Research. 2010; 5(1): 41 – 51.  Mohanachandran P, Sindhumol P. and Kiran T. Enhancement of solubility and dissolution rate: An overview, International Journal of Comp. Pharmacy.2010;4(1): 1-10.  Aulton M. Pharmaceutics: The science of dosage form design. 2nd Edition. USA: Churchill Livingstone.2002; 15. 16

×